Solid Biosciences LLC (SLDB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Solid Biosciences LLC.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 8.10 $ — 58% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -100.0% failed
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 117.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 167 m net cash passed
- Operating cash flow covers the profits of the last three years 45 m failed
- Return on capital at 15% or higher, or up versus two years ago -90.0% failed
- Insiders hold at least 10% or are net buyers 0.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 118.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.98 | -2.51 – -1.67 | 0 | 0.6% | 12 |
| 12/31/2027 | -1.96 | -2.33 – -1.56 | 11 | 1.1% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.43 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.80 | – | 3 | -34.00 | -1,363.50 | -30 | -30 |
| 2025: Q1 | -0.59 | – | 0 | – | – | -32 | -32 |
| 2025: Q2 | -0.42 | – | 0 | – | – | -37 | -38 |
| 2025: Q3 | -0.48 | – | 0 | – | – | -34 | -34 |
| 2025: Q4 | -0.53 | – | 0 | -100.00 | – | -54 | -54 |
| 2026: Q1 | -0.52 | – | 0 | – | – | -47 | -47 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -26 | -22 | -16.80 | -20 | -84 | 41 |
| 2017 | 0 | -55 | -52 | -24.25 | -43 | -59 | 76 |
| 2018 | 0 | -76 | -75 | -33.72 | -70 | 125 | 140 |
| 2019 | 0 | -119 | -117 | -43.64 | -93 | 80 | 103 |
| 2020 | 3 | -86 | -88 | -25.50 | -57 | 132 | 171 |
| 2021 | 14 | -72 | -72 | -10.14 | -78 | 208 | 232 |
| 2022 | 8 | -106 | -86 | -10.10 | -98 | 212 | 260 |
| 2023 | 0 | -104 | -96 | -4.83 | -94 | 126 | 165 |
| 2024 | 0 | -130 | -125 | -3.06 | -100 | 137 | 189 |
| 2025 | 0 | -179 | -174 | -1.99 | -156 | 180 | 233 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Solid Biosciences Inc. entwickelt Therapien für neuromuskuläre und kardiale Erkrankungen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 121 |
| Headquarters | Charlestown, MA |
| Address | 500 Rutherford Avenue, 02129 Charlestown, United States |
| Phone | 617 337 4680 |
| Website | solidbio.com |
| IPO Date | 26. Jan 2018 |
| ISIN | US83422E2046 |
| Stock Split | 1:15 on 10/28/2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ian F. Smith A.C.A., C.P.A. | Executive Chair | 1966 |
| Alexander G. Cumbo | President, CEO & Director | 1971 |
| Ilan Ganot | Co-founder, Strategic Advisor to the CEO & Director | 1974 |
| David Tyronne Howton Jr., J.D. | COO & Secretary | 1972 |
| Gabriel Brooks M.D. | Chief Medical Officer | 1977 |
| Annie Ganot | Co-Founder & VP of Patient Advocacy | – |
| Kevin Tan C.F.A. | CFO & Treasurer | 1978 |
| Paul Herzich | Chief Technology Officer | 1978 |
| Nicole Anderson | Senior Director of Investor Relations & Corporate Communications | – |
| Jessie Hanrahan Ph.D. | Chief Regulatory & Preclinical Operations Officer | 1976 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.